Get started
BioNTech SEBioNTech SEBioNTech SE

BioNTech SE

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BNTX chart


Full chart

BNTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪27.32 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.10 USD
Net income (FY)
‪1.01 B‬ USD
Revenue (FY)
‪4.13 B‬ USD
Shares float
‪239.44 M‬
Beta (1Y)
1.14

About BioNTech SE


Sector
Health Technology
Industry
Biotechnology
CEO
Ugur Sahin
Website
biontech.de
Headquarters
Mainz
Founded
2008
FIGI
BBG00Q70B3V1
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BNTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where BNTX is featured.

See all sparks